By Kamal Choudhury and Christy Santhosh
(Reuters) -The U.S. Food and Drug Administration on Thursday approved Kura Oncology and Japanese partner Kyowa Kirin's once-daily pill, Komzifti, to treat a rare form of blood cancer that has returned or stopped responding to treatment.
The drug is approved for acute myeloid leukemia patients with an NPM1 mutation, a genetic change found in about 30% of cases.
Acute myeloid leukemia is an aggressive cancer of the blood and bone marrow.
Kura said the drug will be available within the next few business days at a price of $48,500 for a one-month supply.
With the approval, Kura's drug now competes with Syndax Pharmaceuticals' Revuforj, which was approved for the same indication by the FDA last month.
Komzifti’s approval comes with a boxed warning for differentiation syndrome and an additional warning for QTc interval prolongation, a delay in the heart’s electrical recovery after a beat, and potential harm to unborn babies.
A boxed warning is the U.S. Food and Drug Administration’s strongest alert for serious or life-threatening risks and appears prominently on a drug’s label to warn doctors and patients.
Revuforj carries a boxed warning for QTc interval prolongation, giving Kura “a significant competitive advantage,” according to Wedbush analysts.
Kura's Chief Medical Officer Mollie Leoni said the risk of QTc prolongation with Komzifti is low, adding it is “extraordinarily unlikely” to lead to a boxed warning.
The company said it is in dialogue with the FDA about potential steps post-approval that could help refine the labeling.
Under the terms of its collaboration with Kyowa, Kura is responsible for manufacturing Komzifti and will lead commercialization in the United States, while Kyowa handles commercial strategy and development outside the U.S.
Analysts, on average, expect Komzifti to have annual sales of $1.32 billion by 2031, according to LSEG data.
(Reporting by Kamal Choudhury and Christy Santhosh in Bengaluru; Editing by Shailesh Kuber and Tasim Zahid)
latest_posts
- 1
FDA updates risk classification for voluntary shredded cheese recall - 2NASA says Maven spacecraft that was orbiting Mars has gone silent
- 3Impact of NIH funding reductions felt in cancer and infectious disease trials
- 4Which game do you cherish observing live? Vote!
- 523 Most Amusing Messages At any point Sent Among Youngsters and Their Folks
- The new queen of country music has no scandals and no gimmicks — and just broke a record set by Taylor Swift
- 5 Advancement Developments in Biotechnology
- A definitive Manual for Well known Fragrances
- Activists guilty over Palestine protest breach
- Ukraine demands army of 800,000 under peace plan
- Elite Execution Wall televisions for Film Darlings
- Israel faces widespread condemnation as NGO ban comes into effect
- Artemis II astronauts race to set a new distance record from Earth and behold the moon's far side
- Tech Patterns 2023: 12 Advancements to Keep an eye Out For
